Ofatumumab in refractory chronic lymphocytic leukemia: experience through the French early access program.
Fiche publication
Date publication
février 2015
Journal
Clinical lymphoma, myeloma & leukemia
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FORNECKER Luc-Matthieu
Tous les auteurs :
Dupuis J, Brice P, François S, Ysebaert L, de Guibert S, Levy V, Leprêtre S, Choquet S, Dilhuydy MS, Fornecker L, Morel V, Tempescul A
Lien Pubmed
Résumé
The Autorisation Temporaire d'Utilisation (ATU) is an early access program available in France for drugs aimed at treating severe diseases not yet covered by a marketing authorization, for patients without any other therapeutic option and who cannot be included in a clinical trial.
Mots clés
Aged, Antibodies, Monoclonal, administration & dosage, Antineoplastic Agents, administration & dosage, Drug Resistance, Neoplasm, Female, France, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Male, Middle Aged, Retrospective Studies, Treatment Outcome
Référence
Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):e43-6